How it works
In a prior authorization request, the prescriber sends the health plan information showing that the patient meets the plan's rules for a drug. For GLP-1 medicines, plans often ask for a diagnosis, a recent BMI, weight-related conditions and records of earlier treatment. The plan or its pharmacy benefit manager then approves or denies the request.
Approval is often time-limited. Many plans require a renewal request after several months, which may ask for proof of weight loss or continued use.
Related rules
Prior authorization is often paired with other utilization rules. Step therapy requires a patient to try a lower-cost drug first. Quantity limits cap how much of a drug the plan will pay for in a period. A drug must also be on the plan's formulary to be covered at all.
Regulation
The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) set decision deadlines starting in 2026 for Medicare Advantage, Medicaid and CHIP plans: 72 hours for urgent requests and 7 calendar days for standard requests. Those deadlines apply to medical items and services, not to drugs. In 2026 CMS proposed a separate rule that would set deadlines for drug prior authorization.
Prior authorization and GLP-1 medicines
Employer and individual plans decide whether to cover GLP-1 medicines for weight loss, and many cover them only for type 2 diabetes. Medicare law has long excluded drugs used for weight loss from Part D. Under the Medicare GLP-1 Bridge, which runs from July 1, 2026 through December 31, 2027, Part D enrollees who meet clinical criteria can get selected GLP-1 medicines for weight reduction, and the prescriber must submit a prior authorization request.
People whose plan denies coverage, or who have no drug coverage, can pay without insurance. Options are compared on the without insurance page. How to check whether a plan covers Wegovy or Zepbound, and what to do after a denial, is on the insurance coverage page. Some online programs file the request for the patient: Ro checks coverage and handles prior authorization for brand-name Ozempic, Wegovy and Zepbound pens, and others are listed under online programs that work with insurance.
Check GLP-1 coverage, or compare programs without PA
See also
References
- CMS: Interoperability and Prior Authorization Final Rule (CMS-0057-F) fact sheet. cms.gov
- CMS: Medicare GLP-1 Bridge. cms.gov
- KFF: What to know about the BALANCE model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge (May 11, 2026). kff.org
Last updated . Category: Insurance & cost. Browse all 38 WikiTelehealth entries.